Neurimmune announced today that it has sold a portion of its royalty interest in cliramitug to Royal

AlTi Global Inc. trimmed its position in Royalty Pharma PLC (NASDAQ: RPRX) by 50.5% in the first qua

Chicago Partners Investment Group LLC purchased a new stake in Royalty Pharma PLC (NASDAQ: RPRX) in

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RP

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should c

NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that i

TD Cowen analyst Steve Scala maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the pri

Teva will advance TEV-'408 into a Phase 2b vitiligo study after Phase 1b data showed skin pigmen

Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expandin

Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the

JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raise

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.30 per share which beat the analyst c

Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and

Royalty Pharma plc (NASDAQ:RPRX) today announced a research and development (R&D) co-funding agr

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with rep

Zymeworks Inc. (NASDAQ:ZYME) and Royalty Pharma plc (NASDAQ:RPRX) today announced an agreement for $

Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investo

  During the session on Thursday, 461 stocks hit new 52-week lows.

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn